Science & Skepticism

Energy Healing and Cancer Research: What the Science Actually Shows

By Keigan Cullen  ·  June 30, 2026

What Is Energy Healing, and Why Are Scientists Studying It?

Energy healing goes by many names: biofield therapy, therapeutic touch, healing touch, Reiki, external Qigong, pranic healing — but the underlying premise across all of them is similar: that human beings generate and interact with fields of energy, and that a trained practitioner can influence those fields in ways that support health.

The National Center for Complementary and Integrative Health (NCCIH) formally classifies these practices as “energy therapies” and defines them as techniques involving the channeling of healing energy through the hands to restore balance and support the body's own processes. What that mechanism actually is, at a physical or biological level, remains genuinely unknown, and researchers are the first to say so.

That uncertainty, though, is not the same as dismissal. Acupuncture was once considered fringe medicine; it now sits inside multiple evidence-based oncology guidelines. Researchers at some of the world's leading cancer institutions — including MD Anderson Cancer Center in Houston — have been running controlled studies on biofield therapy for over a decade, not because the question is settled, but because the early results were odd enough to warrant serious investigation.

So what has that investigation actually found?

The Research Landscape: From Clinical Trials to the Lab

Before looking at specific studies, it helps to understand how this research is structured, because it spans two quite different domains.

Clinical trials test biofield therapies on human patients, measuring outcomes like pain, anxiety, fatigue, and quality of life. These studies face real methodological challenges: it's difficult to design a credible placebo for a hands-on therapy, and patients' expectations can shape their responses in ways that are hard to control for.

Preclinical studies work in cell cultures and animal models. They sidestep the placebo problem (cancer cells don't expect anything) and can examine biological mechanisms directly. The tradeoff is that animal and cell results don't automatically translate to human outcomes, and this field is still building the case for why they might.

A 2010 systematic review published in the International Journal of Behavioral Medicine examined 66 clinical studies across a range of biofield therapies including Reiki, therapeutic touch, healing touch, and external Qigong. (Jain & Mills, 2010) The reviewers found strong evidence that these approaches reduce pain intensity in chronic pain populations, moderate evidence for reducing pain in cancer patients and hospitalized populations, and moderate evidence for reducing agitated behavior in dementia. Effects on fatigue and quality of life in cancer patients were described as equivocal: promising in places, but not yet consistent enough for firm conclusions.

This is where the clinical evidence stood heading into the 2010s: genuinely interesting, methodologically messy, and clearly warranting further study.

The preclinical work, meanwhile, had started producing results that were harder to ignore.

What MD Anderson Found: Biofield Therapy and Pancreatic Cancer

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers known to medicine. Fewer than 13% of patients survive five years from diagnosis, and most conventional treatments, including immunotherapy, have limited impact. Researchers at MD Anderson have been looking at whether biofield therapy might influence this cancer's behavior at the cellular level.

A 2026 study published in Cancer Medicine represents the most comprehensive investigation of this question to date. (Yang et al., 2026) The research team, led by Peiying Yang and Lorenzo Cohen, ran a series of both in vitro and in vivo experiments using multiple human and mouse pancreatic cancer cell lines. Three separate biofield therapists participated, all trained in the same standardized method, and the study included rigorous sham controls where a non-practitioner mimicked the therapist's movements without engaging in the technique itself.

The results were notable across several dimensions.

Cancer cell growth was significantly reduced in cells exposed to biofield therapy compared to both the sham control and the incubator control groups. This held across multiple cell lines and was replicated across more than eleven separate experiments with different therapists. Normal pancreatic ductal epithelial cells, by contrast, showed no significant reduction — a finding the researchers describe as suggesting some degree of cancer-cell specificity.

Under transmission electron microscopy, the mitochondria of treated cancer cells showed striking structural changes: swelling, disordered cristae, and altered dimensions compared to control cells. The researchers also found that biofield therapy increased G1 cell cycle arrest (essentially halting cell division) across multiple pancreatic cancer cell lines.

One of the more mechanistically interesting findings involved a protein called FOXM1, a master regulator of cell cycle progression that is overexpressed in pancreatic cancer and associated with poor outcomes across 39 tumor types. Biofield therapy significantly downregulated FOXM1 expression. When researchers knocked out or overexpressed FOXM1 in cancer cells using CRISPR and other gene-editing tools, they found this modified the cells' response to biofield treatment, suggesting FOXM1 is at least partially mediating the effect rather than simply correlating with it.

The team also measured cell membrane voltage potential, a property increasingly recognized as relevant to cancer behavior. Biofield-treated cells showed a roughly 37% reduction in voltage potential, a shift toward hyperpolarization that research in bioelectricity associates with suppression of malignant behavior.

In orthotopic mouse models, where human pancreatic cancer cells were implanted directly into the pancreases of mice, biofield therapy did not significantly reduce primary tumor size. But it did significantly reduce liver metastasis. Mice in the biofield therapy group had approximately 70% fewer liver nodules than sham control animals, a result that held across two separate PANC-1 studies and was replicated in a third study using mouse KPCY cells.

The researchers are careful about what these results mean. These are preclinical findings. The mechanisms aren't fully understood. The physical basis for biofield therapy (whether electromagnetic fields, biophoton emissions, or something else entirely) was not directly measured in these experiments. But the consistency of effects across multiple cell lines, multiple therapists, and multiple animal models is not the kind of result researchers typically see from noise.

Earlier Preclinical Work: Lung Cancer and Immune Modulation

The pancreatic cancer findings didn't emerge in a vacuum. The same research group at MD Anderson had been building this body of work for years using lung carcinoma models.

A 2019 study in Integrative Cancer Therapies found that human lung cancer cells (A549) exposed to a biofield therapist showed reduced cell viability and downregulation of pAkt (Yang et al., 2019), a protein involved in cell survival and proliferation. In mouse Lewis lung carcinoma models, tumor volume in the biofield therapy group was significantly smaller than in controls, with the effect being most pronounced when treatment began while tumors were still small. The researchers also found that the therapy appeared to reduce the inflammatory chemokine MCP-1 in the blood of treated animals, increase tumor-infiltrating CD8+ cytotoxic T-cells, and reduce regulatory T-cells that typically suppress immune responses against tumors.

A follow-up 2020 study expanded the investigation. (Yang et al., 2020) This experiment did not find significant differences in tumor volume, possibly because the 60-minute session duration increased tumor necrosis to levels that complicated growth measurement. But it did find increased apoptotic cell death, significant shifts in immune cell profiles within the tumor microenvironment, and a meaningful reduction in cancer stemness markers including SOX2. Cancer stem cells are thought to drive tumor initiation, recurrence, and metastasis; finding that biofield therapy reduces their markers, even in a small animal study, is the kind of result that earns a follow-up experiment.

Across both lung carcinoma studies, the animals exposed to biofield therapy also behaved differently during sessions, clustering together, remaining calmer, moving less than controls. The researchers note this as a possible indicator of sympathetic nervous system modulation, though they acknowledge it remains speculative.

The Clinical Picture: Pain, Anxiety, and Quality of Life

Where does all this leave patients who are currently living with cancer and considering whether energy healing might be useful to them?

The clinical evidence is most consistent in one area: pain. The 2010 systematic review found moderate evidence — meaning at least one high-quality randomized controlled trial with supporting data — that biofield therapies reduce acute pain in cancer patients. A 2012 review in the Clinical Journal of Oncology Nursing reached similar conclusions (Anderson & Taylor, 2012), noting that several well-designed studies found cancer patients receiving biofield treatments during chemotherapy experienced measurable reductions in pain compared to control groups.

The evidence for fatigue and quality of life is less clear. Some studies show improvement; others find no significant difference. Researchers point to the heterogeneity of patient populations, treatment protocols, and outcome measures as making direct comparison difficult. This doesn't mean the effect isn't there; it means the field hasn't yet produced the kind of large, well-controlled trials needed to determine its size and consistency.

Anxiety reduction in hospitalized patients, including those undergoing cancer treatment, shows moderate evidence of benefit. A reduction in anxiety during chemotherapy or before surgery is not a trivial outcome; it affects treatment experience, potentially immune function, and quality of life in ways that matter to patients.

Clinical applications of biofield therapy should always sit alongside conventional cancer treatment, not as replacements for it. Researchers and practitioners agree on this point consistently.

Proposed Mechanisms: How Might This Work?

The question of mechanism is where scientists are most candid about the gaps in understanding. Biofield therapy demonstrably produces measurable biological changes in controlled settings. Why it does so is much less clear. Several pathways are being explored, and they aren't mutually exclusive.

Electromagnetic Fields

The human body generates electromagnetic fields (EMFs), and this is not controversial — it's how electrocardiograms and EEGs work. What is less settled is whether a practitioner's EMF output during a biofield session can interact meaningfully with biological targets in a recipient. Some researchers have found that specific EMF patterns, when applied to cancer cells in culture, reduce proliferation. The “Harribance Configuration,” a distinctive gamma brainwave pattern identified via quantitative EEG in the practitioner used in the 2019 and 2020 MD Anderson lung studies, has itself been digitized and applied to melanoma cells in culture, where it decreased cell proliferation. This suggests the signal itself, not just the person, may carry biological information, though this remains an open question.

Biophoton Emissions

All living organisms emit ultra-weak photon emissions, sometimes called biophotons, at levels far below visible light. Some researchers propose these emissions carry biological information involved in cell-to-cell communication and regulation. Whether a healer's biophoton output differs measurably during sessions, and whether it could reach and influence a recipient's cells, hasn't yet been directly tested in the biofield cancer studies reviewed here.

Cell Membrane Voltage and Bioelectricity

Cancer cells are known to carry abnormal membrane voltage states. Restoring more normal voltage through external means appears to suppress malignant behavior — a principle already being used in conventional medicine through tumor-treating fields, the FDA-approved device for glioblastoma. The 2026 MD Anderson pancreatic study found biofield therapy reduced membrane voltage potential by roughly 37%, shifting cells toward a state researchers associate with suppression of cancer behavior. How an external therapy produces this shift remains unresolved.

FOXM1 and Molecular Signaling

As detailed in the pancreatic cancer section above, the 2026 study found biofield therapy downregulates FOXM1, a master regulator of cell cycle progression implicated in tumor growth and metastasis across dozens of cancer types. FOXM1 activity is itself tied to epigenetic modifications, meaning changes in how genes are expressed without altering the DNA sequence itself. This opens the possibility that brief exposures to biofield therapy trigger epigenetic changes in cancer cells, similar to how short-term radiation exposure has been shown to alter DNA methylation patterns. The researchers note this deserves direct investigation.

Immune System Modulation

Across the lung carcinoma studies, biofield therapy consistently shifted immune profiles in ways that favor anti-tumor activity: more CD8+ cytotoxic T-cells, fewer immunosuppressive regulatory T-cells, reduced tumor-infiltrating macrophages. These changes parallel what is being actively pursued in immunotherapy. Whether biofield therapy achieves these shifts through direct EMF interaction, sympathetic nervous system calming, or some other route hasn't been pinned down, but the consistency of the immune findings across separate experiments is notable.

Calcium Channels and Mechanotransduction

Cell migration and division depend heavily on calcium ion flows, which are regulated in part by voltage-gated channels sensitive to electrical and mechanical signals. Several members of the TRP channel family, relevant to pancreatic cancer behavior, are responsive to changes in membrane potential of the kind biofield therapy appears to produce. This connects the voltage findings to a plausible downstream chain of events.

The Interstitium: A Newly Discovered Biological Highway

One development from mainstream anatomy research may turn out to be quietly relevant here, though researchers are careful not to overstate the connection. In 2018, pathologists at NYU published a paper in Scientific Reports (Benias, Wells, Theise et al., 2018) describing something that had been hiding in plain sight: a continuous, body-wide network of fluid-filled spaces woven through connective tissue, found beneath the skin and throughout every major organ system. They called it the interstitium. A 2021 follow-up in Communications Biology (Cenaj, Allison, Theise et al., 2021) confirmed the spaces cross organ boundaries, making the network continuous rather than compartmentalized. It had been missed for decades because standard tissue preparation collapses the fluid-filled spaces, making a three-dimensional network look like solid connective tissue. It took live-tissue imaging to reveal it as it actually exists.

Neil Theise, who led the discovery, describes the interstitium not as an organ but as a system: a body-wide communication network filled with hyaluronic acid and collagen bundles that form a flexible lattice. The collagen is piezoelectric: physically stressed collagen generates electrical current independently of the nervous system. Body movement, the pulse of blood vessels, the rhythm of digestion — all push fluid through this network and produce continuous bioelectric activity throughout the body.

Crucially for this discussion, the interstitium also appears to be a conduit for cancer metastasis. Tumor cells that reach it may travel through into the lymphatic system, which could help explain some patterns of spread. The 2026 MD Anderson pancreatic study found significant reduction in liver metastasis in biofield-treated animals. Whether biofield therapy might influence interstitial fluid dynamics or the bioelectric signaling within it cannot yet be answered, but the anatomy now exists to ask the question in a way it didn't before 2018.

Research on acupuncture adds a further thread: a 2021 study at the Osher Center injected a fluorescent dye into an acupuncture point and watched it migrate through interstitial spaces along a path matching the classical meridian. That result doesn't prove the connection, but it does provide a candidate physical structure for something that previously had no anatomical explanation at all.

The Biology of Belief

Any honest account of energy healing research has to reckon with the placebo effect — not as a dismissal of the field, but because placebo is far more biologically sophisticated than most people realize, and understanding it actually strengthens the case for taking biofield research seriously.

The standard framing treats placebo as a “fake” effect. That picture has been significantly complicated. Harvard's Ted Kaptchuk found that patients with irritable bowel syndrome who were told openly they were receiving placebos — without any deception — still improved significantly more than controls. A 2018 randomized trial extended this to cancer care (Hoenemeyer, Kaptchuk et al., 2018): cancer survivors knowingly taking placebo pills reported a 29% improvement in fatigue severity, a statistically significant, medium-effect-size result.

These aren't subjective impressions. Placebo effects involve measurable biological events: the release of endogenous opioids, cannabinoids, and dopamine; modulation of the hypothalamic-pituitary-adrenal axis; changes in inflammatory signaling. A 2024 study in Nature identified a specific neural circuit — from the rostral anterior cingulate cortex to the pontine nucleus — that mediates placebo analgesia through identifiable brain pathways.

The nocebo effect runs the same mechanism in reverse: negative expectations, a frightening prognosis delivered without care, a side-effect list recited before treatment, produce real measurable harm through stress pathway activation, cortisol elevation, and altered hippocampal and prefrontal activity.

All of this matters for biofield therapy research in a direct way. The preclinical studies reviewed here are designed to eliminate the placebo variable entirely: cancer cells and laboratory mice cannot form expectations. When biofield therapy produces changes in cell proliferation or tumor microenvironment in these models, expectation is categorically ruled out as an explanation. For human patients, the placebo pathway is almost certainly active during a biofield session, and that isn't a flaw. A practitioner's calm, focused presence may activate the endogenous opioid system, reduce cortisol, and shift immune profiles in ways that genuinely ease suffering. Those are real biological effects, regardless of what produced them.

It is why rigorous biofield studies now use sham controls, where a non-practitioner mimics the therapist's movements without the technique. When effects persist against sham controls, something beyond expectation is operating. When they don't, that's useful information too.

None of these mechanisms has been directly measured during an active biofield session. Each represents a credible hypothesis supported by adjacent science rather than direct proof. What the body of research reviewed here adds is a set of specific, testable molecular and biological targets: FOXM1, cell voltage potential, interstitial signaling, immune cell profiles. The field now has more precise tools to work with than it did even five years ago.

What the Research Doesn't Yet Tell Us

Honest engagement with this research means being clear about what it can't yet tell us.

All of the most compelling mechanistic evidence is preclinical. Cell cultures and mouse models are informative but not sufficient. What inhibits cancer cell growth in a petri dish, or slows a tumor in a mouse, may or may not translate to meaningful outcomes in human patients with complex disease.

Sample sizes in the animal studies are small. The 2019 and 2020 lung carcinoma studies involved groups of 9–10 mice. The 2026 pancreatic study was more substantial, but orthotopic mouse models are still a long way from clinical evidence in humans.

Most of the preclinical work has involved a very small number of practitioners. Effects may be practitioner-specific, technique-specific, or dose-specific in ways that haven't been fully characterized. The 2026 study is notable for replicating its in vitro findings across three therapists using a standardized protocol, which addresses some of this concern, but more replication with different practitioners, different techniques, and different institutions is needed.

Finally, the physical mechanism remains unmeasured. Researchers have not yet directly detected or characterized whatever it is that a biofield therapist emits during a session, which makes it difficult to standardize, optimize, or replicate conditions with precision.

None of these limitations mean the research is without value. They mean it is genuinely early-stage, and the results to date are interesting enough to justify continuing.

Why It Matters and Where Research Is Headed

If the findings from preclinical biofield therapy research eventually translate to clinical benefit, even in a supporting or adjuvant role, the implications would be significant. Pancreatic cancer, in particular, has few effective options. Any approach that reduces metastatic spread, even modestly, addresses one of the primary drivers of mortality in this disease.

More broadly, the research is interesting for what it suggests about the relationship between human biological systems and external fields. The FDA approval of tumor-treating fields — which use electrical fields delivered via electrodes to treat glioblastoma and other cancers — demonstrates that this category of intervention can move from hypothesis to medical practice. Biofield therapy research is asking a related, if more radical, question: whether human-generated fields can do something similar, without a device.

Researchers working in this area consistently call for larger trials, better standardization of practitioners and protocols, direct measurement of proposed mechanisms, and comparison with other complementary approaches. The National Center for Complementary and Integrative Health recognizes biofield therapies as a legitimate area of inquiry, and peer-reviewed publications in this space are appearing in respected oncology and integrative medicine journals.

For anyone living with cancer or supporting someone who is, the practical message from this research is modest but real. Biofield therapies are generally considered safe, appear to offer meaningful support for pain and anxiety management in cancer care, and are being investigated at serious research institutions for potential effects on cancer biology itself. They belong in the conversation about integrative oncology, not as alternatives to conventional treatment but as complementary approaches worth understanding and, where appropriate, pursuing.

FAQ

Summary

Energy healing and cancer research occupies a genuinely unusual space: ancient practice meeting rigorous laboratory science, with results that don't fit neatly into either a dismissive or credulous frame.

The preclinical evidence from MD Anderson's research group, particularly the 2026 pancreatic cancer study and the earlier lung carcinoma work, shows that biofield therapy can produce measurable biological changes in cancer cells: reduced proliferation, cell cycle arrest, mitochondrial disruption, downregulation of cancer-promoting proteins, and reduced metastasis in animal models. These results are consistent, have been replicated across multiple cell lines and practitioners, and appear in peer-reviewed journals.

The clinical evidence, meanwhile, supports biofield therapy as a useful complementary intervention for cancer-related pain and anxiety, with some suggestion of quality-of-life benefits and immune effects that warrant further study.

What the research can't yet tell us — and what researchers consistently acknowledge — is whether these preclinical findings will translate into meaningful clinical outcomes in human patients, what the precise mechanism is, or how to standardize and optimize these therapies for consistent use.

This is early-stage research with real results. It deserves attention, honest appraisal, and continued investigation.

Referenced Studies

The findings discussed in this article draw from the following peer-reviewed publications. All are open-access or publicly accessible.